Topics

Companies Related to "Crescita Therapeutics Signs Pliaglis Licensing Agreement with Cantabria" [Most Relevant Company Matches] RSS

16:15 EDT 20th September 2019 | BioPortfolio

Here are the most relevant search results for "Crescita Therapeutics Signs Pliaglis Licensing Agreement with Cantabria" found in our extensive corporate database of over 50,000 company records.

Showing "Crescita Therapeutics Signs Pliaglis Licensing Agreement with Cantabria" Companies 1–25 of 2,400+

Relevant

Hyperion Therapeutics, Inc.

Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of therapies that address critical unmet needs and underserved patient populations in the areas of gastroenterology and hepatology. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of Medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-...


Immunomic Therapeutics, Inc. and ZENOAQ

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with ...

BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a promising company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv Universit...


Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly in the metastatic stage. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activi...

PeriCor Therapeutics, Inc.

PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to improve treatment and patient outcomes in acute-care settings of ischemia/reperfusion injury and heart failure. In August 2007, PeriCor granted worldwide development and commercialization rights for its firs...

California Innovations

California Innovations is the worldwide market leader in insulated products. In 2004, the company acquired the Arctic Zone® brand of coolers. Arctic Zone is a leading brand in the insulated products marketplace. In 2005, the company entered into a licensing agreement with Columbia Sportswear Company® to market coolers, lunch packs, baby bags and drin...

SmartSign

SmartSign is one of America's fastest growing e-commerce companies and parent of JustBathroomSigns, MySafetySign, and more than 50 other sites. The company manufactures and distributes a wide range of signs, tags, mats, and labels. By positioning “signs as solutions,” SmartSign has taken a novel approach to ordering signs. Through highly targeted, ...

Ascenta Therapeutics, Inc.

Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company located in the Greater Philadelphia area. The company is dedicated to efficient oncology drug development and has a portfolio of apoptosis-triggering small molecules that target protein-protein interactions, including two clinical compounds AT-101 and AT-406. In June 2010, A...

ARTEMISPharmaceuticals GmbH

ARTEMIS has developed the ArteMice™ platform, a combination of rapid and sophisticated gene vector design, efficient and expert ES cell transfection techniques, novel blastocyst injection techniques and the patented CreER gene switch. Together the ArteMice™ platform makes sophisticated, genetically modified mice for target validation, ADME/T and basic research available faster than ever before...

Ceptaris Therapeutics Inc.

Ceptaris Therapeutics Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of CTCL. If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to trea...

CANbridge Life Sciences, Ltd.

CANbridge Life Sciences, Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or ...

Admune Therapeutics

Admune Therapeutics, a clinical stage biotechnology company, was founded by a highly experienced team of scientists and business people with a proven track record in producing successful biomedical products. Admune Therapeutics is affiliated with Marine Polymer Technologies, Inc. (MPT), a provider of groundbreaking medical solutions focused in the areas of...

Ceptaris Therapeutics, Inc.

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechloretham...

ADC Therapeutics Sarl

ADC Therapeutics (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of ...

International Food and Agricultural Trade Policy Council

The WTO’s Doha Round negotiations are at a crucial stage. Though there has been some progress towards convergence of different views, many of the key elements of an agricultural agreement are still to be decided. The deadline of April 30 established by Ministers in Hong Kong for the agreement on modalities has been missed, and such an agreement may not come for several weeks. Without the agricul...

BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medic...

Yaupon Therapeutics, Inc.

Yaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). Based upon results of a recently completed trial, Yaupon intends to file a new drug application (...

Transgene SA

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for the treatment of cancers and infectious diseases. Transgene’s products are major technological breakthroughs. They use well tolerated viruses to indirectly or directly kill infected ...

XyloCor Therapeutics Inc.

XyloCor Therapeutics is a private biopharmaceutical company developing novel gene therapy for people with unmet medical need from advanced coronary artery disease. XyloCor is focused on developing its lead product, XC001, for patients with refractory angina with no treatment options and its secondary product, XC002, for patients with cardiac tissue dama...

Galderma Pharma S.A.

Galderma KK, the fully-owned Japanese arm of Galderma, was established in 1996. It has been marketing the topical anti-fungal product Pekiron(R) Cream 0.5% (Loceryl(R)) under a licensing agreement with Kyorin Pharmaceutical since 2002. With the introduction of Differin(R) Gel 0.1% in Japan, Galderma KK, aims to provide comprehensive scientific information to prescribers and medical institution...

LionsGate Technologies Inc.

LionsGate Technologies (LGTmedical) develops globally accessible mHealth solutions. The Vital Signs DSP™ is the company’s proprietary signal processing platform for the development and commercialization of ultra-low cost vital signs monitoring applications in mHealth. LGTmedical is developing a suite of mHealth technologies to meet the important ...

Sotera Wireless, Inc.

Sotera Wireless, Inc. is a medical device company dedicated to development, marketing and sale of a new generation of comprehensive vital signs monitoring. Sotera's mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable rapid response and early intervention, all without limiting the patient's freedom of movement...

Tactical Therapeutics, Inc.

Tactical Therapeutics, Inc., is a privately funded company, that has developed a patented lead therapeutic, CTO, for glioblastoma and other solid cancers. Four Phase I trials in one hundred patients have been completed, and two Phase II trials are planned for rGBM and nGBM. The company is pursuing partnering, co-development and/or licensing strategies to e...

Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-...

Anacor Pharmaceuticals, Inc.

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-...


More From BioPortfolio on "Crescita Therapeutics Signs Pliaglis Licensing Agreement with Cantabria"

Quick Search

Corporate Database Quicklinks